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1. Abbreviations 
 
ACEI  angiotensin-converting enzyme inhibitors 
AIDS  acquired immunodeficiency syndrome 
ARB  angiotensin receptor blockers 
BMI  body mass index 
CI  confidence interval 
CHD  coronary heart disease 
CHF  congestive heart failure 
CKD  chronic kidney disease 
eGFR    estimated glomerular filtration rate 
ESRD  end-stage renal disease 
HIV   human immunodeficiency virus 
HR  hazard ratio 
ICD-9-CM international classification of diseases, ninth revision clinical  
modification 
IQR  interquartile range 
MOR  multinomial odds ratio 
RCAV  racial and cardiovascular risk anomalies in CKD 
SD  standard deviation 
TMAO  trimethylamine-N-oxide 
US  United States 
USRDS  United States Renal Data System 
VA  veterans affairs  
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2. Background 
Chronic kidney disease (CKD) is a growing public health problem due to its 
increasing prevalence and strong association with cardiovascular disease, end-stage 
renal disease (ESRD), and mortality.
1
 Although some risk factors of CKD, such as 
diabetes mellitus and hypertension,
2
 have been established, the identification of novel 
risk factors and interventions applicable to primary care settings may help to ameliorate 
the risk for subsequent adverse outcomes and reduce the global burden of CKD. 
Constipation is the prototype of functional gastrointestinal disorders and one of 
the most prevalent conditions encountered in primary care settings. Approximately 30% 
of the general population experiences problems with constipation during their lifetime,
3
 
with elderly people and women being mostly affected. Although constipation is usually 
perceived as a benign, often self-limited condition,
4
 its chronic symptoms impair 
patients’ quality-of-life and may impose a substantial economic burden on patients and 
society.
5, 6
 Furthermore, recent observational studies have shown an association of 
chronic constipation with increased risk of cardiovascular disease,
7, 8
 and suggested the 
possible involvement of chronic inflammation caused by altered gut microbiota as an 
underlying mechanism for the association.
7, 8
 It is plausible that constipation may also 
be a risk factor for the development of CKD, potentially mediated by altered gut 
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microbiota, or by other intermediate risk factors such as diabetes, use of nonsteroidal 
anti-inflammatory drugs, or lack of physical exercise, which have been associated both 
with constipation
7, 9
 and with CKD progression;
2, 10-12
 however, to the best of my 
knowledge, no prior studies have examined the association between constipation and the 
risk of CKD.  
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3. Study Objective 
In this study, I hypothesized that patients with constipation are at higher risk of 
incident kidney disease and are more likely to experience rapid decline of kidney 
function, and that patients with more severe constipation would have a greater risk of 
such events than those with less severe constipation. To test these hypotheses, I aimed to 
investigate the association of constipation status and its severity with incident CKD and 
ESRD, along with change in estimated glomerular filtration rate (eGFR) using a large 
nationally representative cohort of United States (US) veterans with eGFR of ≥60 
mL/min/1.73 m
2
.   
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4. Methods 
A) Cohort Definition 
I used data from a retrospective cohort study examining risk factors in patients 
with incident CKD (Racial and Cardiovascular Risk Anomalies in CKD [RCAV] 
study).
13
 Figure 1 shows the algorithm for cohort definition. All serum creatinine 
measurements obtained in clinical settings in all US Department of VA health care 
facilities between October 1, 2004 and September 30, 2006 (baseline period) were used 
from the national VA Corporate Data Warehouse LabChem data files.
14
 Overall, 
4,447,691 veterans had at least 1 available serum creatinine measurement, representing 
~94% of all US veterans who received VA health care during this time period.
15
 The 
RCAV cohort included 3,582,478 patients with baseline eGFR ≥60 mL/min/1.73 m2. 
eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) creatinine equation.
16
 After exclusion of patients with missing International 
Classification of Diseases, Ninth Revision Clinical Modification (ICD-9-CM) codes (n = 
11,311) or with erroneous data (n = 66,435), 3,504,732 patients were included in the 
final cohort. 
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B) Data Collection 
Exposures and Covariates 
Constipation was defined as either having at least 2 diagnoses for constipation, as 
identified by the ICD-9-CM (Table 1), that were >60 days apart; or having ≥2 
prescriptions of laxatives of ≥30-day supply each, that were 60365 days apart during 
the baseline period, based on information obtained from VA Pharmacy dispensation 
records.
17
 Constipation severity was also quantitatively defined according to the number 
of different types of laxatives prescribed during the baseline period, and stratified into 
three groups as follows; absent (no laxative), mild (one type of laxative), or 
moderate/severe (≥2 types of laxatives). Sociodemographic characteristics, comorbid 
conditions, medication use, and laboratory characteristics were obtained as previously 
described.
18, 19
 Briefly, data on patients’ age, sex, race, marital status (married, single, 
divorced or widowed), mean per capita income, service connectedness, body mass index 
(BMI), systolic and diastolic blood pressures, comorbid conditions, and medication use 
was obtained from various national VA research data files.
20
 Prevalent comorbidities 
were defined as the presence of relevant ICD-9-CM and Current Procedural 
Terminology codes recorded from October 1, 2004, to September 30, 2006 (Table 1).
18, 
19
 Prevalent coronary heart disease (CHD) was defined as the presence of diagnostic 
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codes for coronary artery disease, angina, or myocardial infarction or procedure codes 
for percutaneous coronary interventions or coronary artery bypass grafting. Bowel 
disorders were defined as the presence of diagnostic codes for inflammatory bowel 
disease, irritable bowel syndrome, or diarrhea. In addition to the information derived 
from VA sources, select socioeconomic indicators using 2004 county typology codes 
(housing stress, low education, low employment, and persistent poverty; Table 2) were 
included. 
 
Outcomes 
The co-primary outcomes of interest were incident CKD, incident ESRD, and 
change in eGFR. Incident CKD was defined as two eGFR levels <60 mL/min/1.73 m
2
 
separated by ≥90 days, and a >25% decrease from baseline eGFR.21 Incident ESRD was 
defined as initiation of maintenance dialysis or preemptive renal transplantation 
occurring between the cohort entry date and September 13, 2011, the last date of 
available event record provided by the United States Renal Data System (USRDS). 
Change in eGFR (i.e., eGFR slope) was calculated in each patient from an ordinary least 
squares regression model using all outpatient eGFR measurements available from the 
cohort entry date to October 13, 2012 (the last date of available serum creatinine 
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measurement), and stratified into 5 categories as follows: <10, -10 to <-5, -5 to <-1, -1 
to 0 (reference), and ≥0 mL/min/1.73 m2/year. The median (interquartile range [IQR]) 
number of eGFR measurements used to calculate eGFR slopes was 10 (5 to 17). 
Information about all-cause mortality was obtained from the VA Vital Status Files.
22
 
 
C) Statistical Analyses 
Data are presented as number (percent) for categorical variables and 
mean±standard deviation (SD) for continuous variables with a normal distribution or 
median (IQR) for those with a skewed distribution. The start of follow-up was the date 
of the first eGFR ≥60 mL/min/1.73 m2 during the baseline period. Patients were 
followed up until death or until the last date of VA contact. The associations of 
constipation status and its severity with outcomes were assessed with the Kaplan-Meier 
method and log-rank tests, and using Cox proportional hazards models (for 
time-to-event analyses) and multinomial logistic regression models (for change in 
eGFR). The proportionality assumption was tested by plotting log [-log (survival rate)] 
against log (survival time) and by scaled Schoenfeld residuals; and showed no 
violations. For the time-to-event analyses, patients were followed up until death or were 
censored at the date of the last encounter, or on October 13, 2012 and September 13, 
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2011 for incident CKD and ESRD, respectively. All associations were examined in 
unadjusted and multivariable adjusted models. Models were incrementally adjusted for 
the following confounders based on theoretical considerations: model 1, unadjusted; 
model 2, adjusted for age, sex, and baseline eGFR; model 3, model 2 variables plus 
prevalent comorbidities (diabetes mellitus, hypertension, CHD, congestive heart failure 
[CHF], cerebrovascular disease, peripheral vascular disease, peptic ulcer disease, 
rheumatic disease, malignancy, depression, liver disease, chronic lung disease, human 
immunodeficiency virus [HIV]/ acquired immunodeficiency syndrome [AIDS], and 
bowel disorders); model 4, model 3 variables plus baseline BMI and systolic and 
diastolic blood pressure; and model 5, model 4 variables plus socioeconomic parameters 
(mean per capita income, marital status, service connectedness, housing stress, low 
education, low employment, and persistent poverty), indicators of sickness (number of 
VA healthcare encounters and cumulative length of hospitalization) and quality of care 
(receipt of influenza vaccination[s]), and use of angiotensin-converting enzyme 
inhibitors (ACEIs), or angiotensin II receptor blockers (ARBs), statins, antidepressants, 
non-opioid analgesics, and opioids at baseline. 
I additionally performed several sensitivity analyses. All outcomes were 
examined in subgroups of patients categorized by baseline age, sex, race, prevalent 
11 
 
diabetes mellitus, hypertension, CHD, CHF, eGFR, and income level. Analyses were 
repeated in a propensity score-matched cohort to account for baseline differences 
arising from dissimilarities in clinical and demographic characteristics of patients with 
and without constipation. Propensity scores for the likelihood of presence versus 
absence of constipation were calculated by logistic regression using all variables 
included in multivariable models and performing a 1:1 nearest-neighbor matching 
without replacement. As death and incident CKD/ESRD are competing events, 
competing risk regressions were also performed using unadjusted models in the overall 
cohort, as well as in the propensity-matched cohort. Of the variables included in 
multivariable adjusted models, data points were missing for race (9.7%), BMI (4.7%), 
blood pressure (1.4%), per capita income (6.9%), and socioeconomic indicators (4.0%). 
Missing values were not imputed in primary analyses but were substituted by multiple 
imputation procedures using the STATA “mi” set of command in sensitivity analyses. 
Because of the large sample size, the significance of differences in the main 
cohort was established based on considerations of biologically or clinically meaningful 
differences. Differences between variables in the overall and propensity-matched 
cohorts were examined by calculating standardized differences, and values >0.1 were 
considered significant. All of the analyses were conducted using Stata/MP version 14 
12 
 
(Stata Corporation, College Station, TX). The study was approved by the institutional 
review boards at the Memphis and Long Beach VA medical centers. 
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5. Results 
Patients’ baseline characteristics overall and those in patients categorized by 
constipation status are shown in Table 3. The mean age at baseline was 60.0 years (SD, 
14.1); 93.2% were male; 15.3% were African American; and 24.7% were diabetic. The 
mean eGFR was 83.8 mL/min/1.73 m
2
 (SD, 15.6). Compared to patients without 
constipation, those with constipation were older and more likely to be African American, 
had a higher prevalence of comorbidities except HIV/AIDS and a lower per capita 
income, and were less likely to be married. They also had more frequent healthcare 
encounters and longer cumulative length of hospitalization during the two-year baseline 
period. The use of ACEIs/ARBs, statins, antidepressants, non-opioid analgesics, and 
opioids and the administration of influenza vaccination(s) were more common in 
patients with constipation. Baseline characteristics were well balanced in the 
propensity-matched cohort (Table 3). 
 
A) Incident CKD 
During a median follow-up of 7.0 years, there were a total of 360,541 events of 
incident CKD (crude rate, 17.2 per 1000 patient-years; 95% CI, 17.217.3), including 
46,022 (crude rate, 33.9 per 1000 patient-years; 95% CI, 33.634.2) and 314,519 (crude 
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rate, 16.1 per 1000 patient-years; 95% CI, 16.016.1) events in patients with and 
without constipation, respectively. As depicted in Figure 2(A)a, patients with 
constipation had a higher cumulative incidence of CKD (log-rank P <0.001). Figure 
3(A) shows the association between constipation status and incident CKD in unadjusted 
and adjusted models. In the crude model, the presence of constipation was associated 
with a higher risk of incident CKD (hazard ratio [HR], 2.08; 95% CI, 2.062.10). 
Although adjustment for covariates resulted in the attenuation of this association, the 
risk of incident CKD remained significantly higher in patients with constipation 
(adjusted HR, 1.13; 95% CI, 1.111.14). Compared to patients with absent constipation, 
those with more severe constipation showed incrementally higher associations with the 
incidence of CKD: log-rank P <0.001, Figure 2(A)b; fully-adjusted HRs [95% CI], 
1.10 [1.091.12] and 1.16 [1.141.18] for mild and moderate/severe constipation, 
respectively (Figure 4(A)). 
 
B) Incident ESRD 
A total of 7,677 patients developed ESRD (crude rate, 0.39 per 1000 
patient-years; 95% CI, 0.380.40), including 902 (crude rate, 0.65 per 1000 
patient-years; 95% CI, 0.610.70) and 6,775 (crude rate, 0.37 per 1000 patient-years; 
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95% CI, 0.360.38) events in patients with and without constipation, respectively. 
Cumulative incidence of ESRD was higher in patients with (versus without) 
constipation (log-rank P <0.001; Figure 2(B)a). Patients with constipation had a 
significantly higher risk of incident ESRD (adjusted HR, 1.09; 95% CI, 1.011.18; 
Figure 3(B)). With increasing constipation severity, a higher cumulative incidence of 
ESRD (Figure 2(B)b) as well as a greater risk of incident ESRD (Figure 4(B)) was also 
observed. 
 
C) Change in eGFR 
Among 3,242,681 patients in the eGFR slope analysis, 119,165 (3.7%), 189,792 
(5.9%), and 905,877 (27.9%) experienced decline in eGFR of <-10, -10 to <-5, and -5 to 
<-1 mL/min/1.73 m
2
/year, respectively, whereas 1,378,842 patients (42.5%) had stable 
or increasing eGFR (≥0 mL/min/1.73 m2/year) (Table 4). Figure 3(C) shows the 
association between constipation status and change in eGFR. Compared to patients 
without constipation, those with constipation were at a greater risk of experiencing more 
progressive eGFR decline, with higher risks seen in patients with faster eGFR decline 
(adjusted multinomial odds ratios [MORs] [95% CI], 1.17 [1.141.20] for eGFR slopes 
<-10, 1.07 [1.041.09] for -10 to <-5, and 1.01 [1.001.03] for -5 to <-1 [versus -1 to 
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<0] mL/min/1.73 m
2
/year); and they also had a higher risk of increasing eGFR (adjusted 
OR [95% CI], 1.09 [1.081.11] for eGFR slopes ≥0 [versus -1 to <0] mL/min/1.73 
m
2
/year). The risk of progressive eGFR decline was higher in patients with mild and 
moderate/severe constipation than those with absent constipation (adjusted MORs [95% 
CI] of eGFR slopes <-10 [versus -1 to <0] mL/min/1.73 m
2
/year, 1.18 [1.141.21] and 
1.30 [1.251.35], adjusted MORs of eGFR slopes -10 to <-5, 1.07 [1.041.10] and 1.12 
[1.091.16], and adjusted MORs of eGFR slopes -5 to <-1, 1.01 [0.991.03] and 1.04 
[1.021.06], respectively; Figure 4(C)). Similarly, the risk of increasing eGFR was 
incrementally higher in those with more severe constipation (adjusted ORs [95% CI] of 
eGFR ≥0 [versus -1 to <0] mL/min/1.73 m2/year, 1.08 [1.061.10] and 1.14 [1.121.17] 
for mild and moderate/severe constipation, respectively; Figure 4(C)). 
 
D) Sensitivity Analyses 
Results were similar in the various sensitivity analyses accounting for 
confounding by indication, competing risk, and missing data (Tables 5 and 6), as well 
as in select subgroups (Figures 5 and 6).  
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6. Discussion 
In the present study, I examined the association of constipation status and its 
severity with incident CKD, incident ESRD, and change in eGFR, using a large cohort 
of US veterans with baseline eGFR ≥60 mL/min/1.73m2, and found that the presence of 
constipation and the severity of constipation were associated with increased risk of 
incident CKD, incident ESRD, and progressive eGFR decline. These findings were 
similarly observed in selected subgroups and were robust to sensitivity analyses 
accounting for confounding by indication, competing risk, and missing data. 
The prevalence of constipation has been shown to be higher in patients with CKD, 
particularly among those undergoing dialysis, than the general population,
23
 mostly due 
to their dietary restrictions, medications like phosphate binders, and high prevalence of 
comorbidities.
24
 In recent years, there has been a growing interest in the association 
between CKD and intestinal environment (often referred to as “CKD-Colonic Axis”), 
showing that CKD can cause significant quantitative and qualitative alterations of gut 
environment, which in turn may contribute to the pathogenesis of CKD progression and 
several CKD-related complications.
25
 However, these studies have focused primarily on 
patients with advanced CKD; and hence, it remains unknown whether the altered gut 
environment is associated with the development of de-novo kidney disease in patients 
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with preserved kidney function. Given the fact that gastrointestinal motility and gut 
environment are interrelated and exert reciprocal effects on each other,
26, 27
 it is 
plausible that constipation, one of the clinical forms of altered gut environment, can be a 
risk factor for kidney disease progression.  
There are several potential mechanisms for the association between constipation 
and the risk of adverse renal outcomes. Recently, emerging evidence has disclosed a 
tight and coordinated connection between gut microbiota and host nutrition, metabolism, 
and immune function,
28
 indicating that disturbance of the gut microbiota is linked to the 
pathogenesis of diverse illnesses, such as metabolic syndrome
29
 and cardiovascular 
disease
30
 through chronic inflammation and/or altered metabolite profiles. For example, 
trimethylamine-N-oxide (TMAO), a gut microbiota-dependent metabolite, has been 
shown to play a significant role in the development and progression of atherosclerosis 
and adverse atherosclerotic cardiac events.
31, 32
 Furthermore, recent metabolomics data 
from the Framingham Heart Study highlight that TMAO levels predict the risk of 
incident CKD in healthy subjects.
33
 Alterations in gut microbiota have also been linked 
to the accumulation of gut-derived uremic toxins such as indoxyl sulfate and p-cresyl 
sulfate,
10
 which in turn appear to accelerate kidney disease progression by causing renal 
fibrosis, inflammation, and oxidative stress.
34
 While a large clinical trial examining the 
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reduction of systemic toxin absorption through gastrointestinal sequestration via 
spherical carbon adsorbent AST-120 has failed to show a benefit towards slowing 
kidney disease progression,
35
 adherence to the medication in this clinical trial was poor, 
and hence it remains unclear if proper administration of this or other similar products 
could be renoprotective. Considering the possible existence of altered gut microbiota in 
patient with constipation, these pathophysiologic mechanisms could serve as a potential 
explanation for the association between constipation and adverse renal outcomes. 
Another plausible mechanism for the observed association may be through 
increased levels of serotonin. Serotonin is synthesized in the gut and incorporated into 
platelets, which, when activated, release serotonin and enhance vasoconstriction and 
thrombus formation, resulting in the development of atherosclerotic plaques.
36
 Previous 
studies have also reported an association between elevated plasma levels of serotonin 
and increased risk of atherosclerotic cardiovascular disease.
37
 Since serotonin synthesis 
and release have been shown to be increased in patients with constipation
38
 and in those 
using certain laxatives,
39
 increased serotonin levels could also explain the underlying 
pathogenesis of kidney disease progression. In addition to these mechanisms, the use of 
certain types of laxatives may directly (e.g., through drug-induced nephrotoxicity) or 
indirectly (e.g., through dehydration or electrolyte disturbances) cause kidney damage, 
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and could potentially contribute to the increased risk of renal events. 
Interestingly, I found a significant association between constipation and the risk 
of increasing eGFR. As previously reported,
40-42
 increasing eGFR has been recognized 
as a predictor of adverse clinical outcomes through loss of muscle mass associated with 
chronic debilitating conditions, and increasing eGFR may also reflect recovery from 
acute kidney injury. Although lean body mass was not measured in this cohort and 
hence precise mechanisms underlying the observed association remain speculative, the 
greater risk of increasing eGFR might reflect a higher incidence of some chronic 
illnesses accompanied by a decline in serum creatinine among patients with constipation. 
Most importantly, however, the associations of constipation with adverse renal 
outcomes still remained statistically significant even after accounting for various 
potential confounders including comorbidities, number of VA healthcare encounters, 
and cumulative length of hospitalization, which highlights the biologically plausible 
link between the gut and kidney and provides additional insights into the pathogenesis 
of kidney disease progression. 
Given the high prevalence of constipation and the simplicity of its assessment in 
primary care settings, this study may also have several clinical implications. First, 
physicians should be aware of the risk of kidney disease progression in patients with 
21 
 
constipation. When evaluating a patient with constipation and reduced kidney function 
in clinical practice, it is also important for healthcare providers to acknowledge the 
excess risk of kidney damage caused by dehydration and use (especially 
over-the-counter use) of nonsteroidal anti-inflammatory drugs. Careful observation of 
kidney function trajectory may thus be required in those patients, particularly among 
those with more severe constipation. Furthermore, if the relationships between 
constipation and renal events are causal, these findings suggest that the treatment of 
constipation through lifestyle modifications (e.g., exercise and high-fiber diet
43,
 
44
) 
and/or use of probiotics
45
 rather than laxatives could potentially reduce the risk of 
adverse renal outcomes and may deserve future clinical trials. 
     This study is notable for its large sample size and for being representative of 
veterans in the entire geographic United States; however, several limitations need to be 
acknowledged. Because the study was observational, the results do not allow us to infer 
causality. It could be argued that constipation may be merely a non-specific marker of 
general illness rather than a causative factor; however, the significant association that 
was robust to adjustment for a wide assortment of confounders, combined with 
plausible mechanistic explanations, raises the possibility of a causal link between 
constipation and renal outcomes. Most of the patients were men; hence, the results may 
22 
 
not be generalizable to women or patients from other geographical areas. This cohort 
was defined on the basis of an eGFR ≥60 mL/min/1.73m2, but markers of earlier stages 
of CKD (e.g., proteinuria) were not available. Because information about subjective 
symptoms of constipation was not available, and constipation status and its severity 
were defined using the ICD-9-CM codes and laxative prescription records during the 
two-year baseline period, it was unable to assess the impact of lifetime duration of 
constipation and its status over the entire follow-up period on the outcomes, and patients 
with constipation might have been misclassified as absent constipation or having less 
severe constipation. Nevertheless, such misclassification would tend to bias the true 
effects toward the null, and the results still demonstrated significant associations of 
constipation with increased risk of renal events. Several statistical methods were applied 
in the sensitivity analyses to address the effect of confounders, but the possibility of 
unmeasured confounders cannot be eliminated. Also, we cannot exclude the possibility 
of nephrotoxicity induced by the long-term use of certain types of laxatives among 
patients with constipation.  
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7. Conclusion 
In this large nationwide cohort of >3 million US veterans, I found that 
constipation status and its severity were associated with a higher risk of incident CKD, 
incident ESRD, and progressive eGFR decline, independent of known risk factors. 
Further studies are needed to elucidate the underlying mechanisms for the associations 
and to determine whether the amelioration of constipation can prevent adverse renal 
outcomes.  
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10. Tables and Figures  
 
Table 1. ICD-9 and procedure (CPT) codes used to define prevalent comorbid conditions 
 
ICD-9 codes  
Comorbid condition ICD-9 code 
Constipation 564.0x 
Hypertension 401-405 
Diabetes mellitus 250.x 
Coronary artery disease 414.0, 414.8, 414.9 
Angina 411, 413 
Myocardial infarction 410-410.9, 412 
PCI 36.03, 36.04, 36.06, 36.07, 36.09 
CABG 36.10-36.17, 36.19 
Congestive heart failure 428-428.9 
Cerebrovascular disease 430-438 
Peripheral arterial disease 
440.0-440.9, 443, 443.x, 38.0, 38.1, 39.50, 39.22, 
39.24, 39.25, 39.26, 39.28 
Chronic lung disease 490-496, 500-505, 506.4 
Dementia 290-290.9 
Rheumatologic disease 710.0, 710.1, 710.4, 714.0-714.2, 714.81, 725 
Peptic ulcer disease 
531-534.9, 531.4-531.7, 532.4-532.7, 533.4-533.7, 
534.4-534.7 
Liver disease 571.x, 572.x, 456.0-456.21 
Malignancy 140-172.9, 174-195.8, 200-208.9, 196-199.1 
HIV/AIDS 042, V08, 795.71 
Depression 296.x 
Bowel disorders 555.x, 556.x, 564.1x, 564.5x, 787.91, 009.x 
 
Procedure (CPT) codes  
Procedure CPT code 
PCI 
92980 92981 92982 92984 92985 92986 92987 92988 92989  
92990 92991 92992 92993 92994 92995 92996 
CABG 
33510 33511 33512 33513 33514 33515 33516 33517 33518 
33519 33521 33522 33523 33533 33534 33535 33536 
 
 
Abbreviations: AIDS = acquired immunodeficiency syndrome; CABG = coronary artery bypass grafting; 
HIV = human immunodeficiency virus; PCI = percutaneous coronary intervention 
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Table 2. Area-based socio-economic indicators 
 
Indicators Definition 
Housing stress 
30 percent or more of households had one or more of these housing 
conditions in 2000: lacked complete plumbing, lacked complete kitchen, 
paid 30 percent or more of income for owner costs or rent, or had more than 
1 person per room. 
Low-education 
25 percent or more of residents 25 through 64 years old had neither a high 
school diploma nor General Educational Development in 2000. 
Low-employment 
Less than 65 percent of residents 21 through 64 years old were employed in 
2000. 
Persistent poverty 
20 percent or more of residents were poor as measured by each of the last 4 
censuses: 1970, 1980, 1990 and 2000. 
 
Note: The Area Health Resources Files (AHRF, http://ahrf.hrsa.gov/) system is issued by the National 
Center for Health Workforce Analysis, Bureau of Health Workforce, Health Resources and Services 
Administration. Within the AHRF, we used select 2004 County Typology Codes from the Economic 
Research Service (ERS), U.S. Department of Agriculture, www.ers.usda.gov. The 2004 County Typology 
Codes were developed for all 3,141 counties, county equivalents, and independent cities in the United 
States. 
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Table 3. Baseline patient characteristics in the overall cohort and propensity-matched 
cohort 
 
 Overall cohort Propensity-matched cohort 
Characteristics 
Total 
Constipation 
Std. 
Diff. 
Constipation 
Std. 
Diff. 
No Yes No Yes 
(n = 3,504,732) (n = 3,251,291) (n = 253,441) (n = 208,979) (n = 208,979) 
Mean age (SD), y 60.0 (14.1) 59.6 (14.1) 64.1 (13.0) 0.33 63.9 (12.3) 63.5 (12.8) -0.031 
Mean eGFR (SD), 
mL/min/1.73m2 
83.8 (15.6) 83.9 (15.5) 82.8 (15.8) -0.08 82.9 (15.5) 83.1 (15.8) 0.01 
Male, n (%) 3,267,365 (93.2) 3,030,680 (93.2) 236,685 (93.4) 0.028 195,507 (93.6) 195,626 (93.6) -0.002 
African 
American, n (%) 
537,191 (15.3) 487,079 (15.0) 50,112 (20.0) 0.096 44,180 (21.1) 43,716 (20.9) -0.005 
Hypertension, n 
(%) 
2,079,730 (59.3) 1,899,132 (58.4) 180,598 (71.3) 0.25 151,774 (72.6) 150,044 (71.8) -0.018 
Diabetes mellitus, 
n (%) 
831,043 (24.7) 749,118 (23.0) 81,925 (32.3) 0.19 69,389 (33.2) 68,462 (32.8) -0.009 
CHD, n (%) 399,833 (11.4) 353,552 (10.9) 46,281 (18.3) 0.21 39,716 (19.0) 39,293 (18.8) -0.005 
CHF, n (%) 152,126 (4.3) 125,624 (3.9) 26,502 (10.5) 0.25  21,680 (10.4) 22,215 (10.6) 0.008 
CVD, n (%) 212,024 (6.1) 180,585 (5.6) 31,439 (12.4) 0.23 26,544 (12.7) 26,203 (12.5) -0.005 
PAD, n (%) 190,548 (5.4) 162,877 (5.0) 27,671 (10.9) 0.21 23,452 (11.2) 23,357 (11.2) -0.001 
Chronic lung 
disease, n (%) 
637,350 (18.2) 558,622 (17.2) 78,728 (31.1) 0.32 67,551 (32.3) 66,434 (31.8) -0.011 
Dementia, n (%) 28,646 (0.8) 22,741 (0.7) 5,905 (2.3) 0.13 4,284 (2.1) 4,487 (2.2) 0.007 
Rheumatologic 
disease, n (%) 
49,021 (1.4) 43,098 (1.3) 5,923 (2.3) 0.075 5,167 (2.5) 4,998 (2.4) -0.005 
Peptic ulcer 
disease, n (%) 
64,990 (1.9) 55,294 (1.7) 9,696 (3.8) 0.13 8,010 (3.8) 8,224 (3.9) 0.005 
Liver disease, n 
(%) 
14,795 (0.4) 10,061 (0.3) 4,734 (1.9) 0.15 3,476 (1.7) 4,042 (1.9) 0.02 
Malignancies, n 
(%) 
355,185 (10.1) 307,105 (9.5) 48,080 (19.0) 0.28 40,777 (19.5) 39,979 (19.1) -0.01 
HIV/AIDS, n (%) 21,247 (0.6) 19,637 (0.6) 1,610 (0.6) -0.001 1,330 (0.6) 1,389 (0.7) 0.004 
Depression, n (%) 323,221 (9.2) 279,955 (8.6) 43,266 (17.1) 0.24 37,499 (17.9) 37,310 (17.9) -0.002 
Bowel disorders, 
n (%) 
145,811 (4.2) 122,835 (3.8) 22,976 (9.1) 0.21 19,212 (9.2) 19,499 (9.3) 0.005 
Median per capita 
income (IQR), $ 
22971 
(11725-36048) 
23258 
(11866-37111) 
19061 
(10647-30613) 
-0.20 
18856 
(10606-30453) 
19119 
(10717-30588) 
0.029 
Married, n (%) 1,880,248 (53.7) 1,758,279 (54.1) 121,969 (48.1) 0.096 107,179 (51.3) 106,522 (51.0) -0.006 
Service 
connected, n (%) 
1,426,273 (40.7) 1,301,738 (40.0) 124,535 (49.1) 0.14 107,187 (51.3) 105,723 (50.6) -0.014 
Mean BMI (SD), 
kg/m2 
29.2 (5.7) 29.2 (5.7) 29.2 (6.2) 0.008 29.3 (6.1) 29.3 (6.3) 0.004 
Mean systolic BP 
(SD), mmHg 
135.4 (19.1) 135.5 (19.1) 134.1 (19.8) -0.075 134.2 (19.2) 134.2 (19.8) -0.002 
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Mean diastolic BP 
(SD), mmHg 
77.2 (11.8) 77.3 (11.8) 75.2 (12.0) -0.19 75.3 (11.9) 75.4 (12.0) 0.011 
ACEI/ARB use, n 
(%) 
773,938 (22.1) 703,531 (21.6) 70,407 (27.8) 0.14 58,796 (28.1) 57,888 (27.7) -0.01 
Statin use, n (%) 506,980 (14.5) 459,218 (14.1) 47,762 (18.9) 0.13 39,531 (18.9) 39,086 (18.7) -0.005 
Antidepressants 
use, n (%) 
622,543 (17.8) 538,862 (16.6) 83,681 (33.0) 0.36 71,663 (34.3) 69,854 (33.4) -0.018 
Non-opioid 
analgesics use, n 
(%) 
827,856 (23.6) 725,729 (22.3) 102,127 (40.3) 0.37 87,710 (42.0) 85,186 (40.8) -0.025 
Opioids use, n 
(%) 
385,838 (11.0) 316,038 (9.7) 69,800 (27.5) 0.46 60,782 (29.1) 59,486 (28.5) -0.014 
Influenza 
vaccination, n(%) 
1,032,254 (29.5) 920,070 (28.3) 112,184 (44.3) 0.33 96,629 (46.2) 93,828 (44.9) -0.027 
Living in area 
with high housing 
stress, n (%) 
1,181,986 (33.7) 1,090,152 (33.5) 91,834 (36.2) 0.067 79,956 (38.3) 80,040 (38.3) 0.001 
Living in area 
with low 
education, n (%) 
364,485 (10.4) 334,018 (10.3) 30,467 (12.0) 0.05 26,885 (12.9) 26,407 (12.6) -0.007 
Living in area 
with low 
employment, n 
(%) 
318,669 (9.1) 292,720 (9.0) 25,949 (10.2) 0.035 22,829 (10.9) 22,374 (10.7) -0.007 
Living in area of 
persistent poverty, 
n (%) 
166,638 (4.8) 152,459 (4.7) 14,179 (5.6) 0.036 12,603 (6.0) 12,190 (5.8) -0.008 
Healthcare 
encounters, n 
(IQR) 
20 (10-38) 19 (10-35) 51 (28-85) 0.77 45 (24-81) 54 (31-88) 0.053 
Cumulative length 
of hospitalization 
(IQR), days 
0 (0-0) 0 (0-0) 0 (0-6) 0.23 0 (0-3) 0 (0-7) 0.017 
 
Note: Data are presented as number (percentage), mean ± standard deviation, or median (interquartile 
range). 
 
Abbreviations: ACEI = angiotensin-converting enzyme inhibitors; AIDS = acquired immunodeficiency 
syndrome; ARB = angiotensin receptor blockers; BMI = body mass index; BP = blood pressure; CHD = 
coronary heart disease; CHF = congestive heart failure; CVD = cerebrovascular disease; DM = diabetes 
mellitus; eGFR = estimated glomerular filtration rate; HIV = human immunodeficiency virus; PAD = 
peripheral arterial disease; Std. Diff. = standardized difference 
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Table 4. Number of patients across categories of change in eGFR stratified by constipation 
status 
 
 
Total 
Constipation 
No Yes 
(n = 3,242,681) (n = 2,996,125) (n = 246,556) 
Change in eGFR,  
mL/min/1.73 m
2
/year  
 
 
<-10 119,165 (3.7) 106,111 (3.5) 13,054 (5.3) 
-10 to <-5 189,792 (5.9) 171,691 (5.7) 18,101 (7.3) 
-5 to <-1 905,877 (27.9) 834,744 (27.9) 71,133 (28.9) 
-1 to <0 649,005 (20.0) 606,329 (20.2) 42,676 (17.3) 
≥0* 1,378,842 (42.5) 1,277,250 (42.6) 101,592 (41.2) 
 
Note: Data are presented as number (percentage). 
*~82% of patients in this category had eGFR <3 mL/min/1.73 m
2
 
 
Abbreviation: eGFR = estimated glomerular filtration rate 
  
37 
 
Table 5. Incident CKD and incident ESRD outcomes associated with (A) constipation 
status and (B) constipation severity in Cox models censored for mortality and in 
competing risk regression models 
 
(A) Constipation status (present vs. absent constipation) 
 
Primary events 
(n, %) 
Competing events 
(deaths; n, %) 
HR (95% CI) SHR (95% CI) 
Unmatched (n = 3,504,732) 
    
Incident CKD 360,541 (10.3) 595,643 (17.1) 2.08 (2.062.10) 1.96 (1.941.98) 
Incident ESRD 7,674 (0.2) 703,419 (20.1) 1.77 (1.651.90) 1.61 (1.501.73) 
PS-matched (n = 417,958) 
    
Incident CKD 77,518 (18.5) 100,089 (23.9) 1.12 (1.101.13) 1.10 (1.081.11) 
Incident ESRD 1,471 (0.4) 128,884 (30.8) 1.15 (1.041.28) 1.12 (1.011.24) 
 
(B) Constipation severity 
 
Primary 
events 
(n, %) 
Competing events 
(deaths; n, %) 
Constipation 
Severity 
HR (95% CI) SHR (95% CI) 
Unmatched  
(n = 3,504,732)   
 
  
Incident CKD 360,541 (10.3) 595,643 (17.1) 
Mild 1.99 (1.962.02) 
1.89 
(1.861.91) 
Moderate/Severe 2.38 (2.342.41) 
2.18 
(2.142.21) 
Incident ESRD 7,674 (0.2) 703,419 (20.1) 
Mild 1.73 (1.581.90) 
1.60 
(1.451.75) 
Moderate/Severe 2.08 (1.882.31) 
1.82 
(1.642.02) 
PS-matched  
(n = 417,958)   
 
  
Incident CKD 77,518 (18.5) 100,089 (23.9) 
Mild 1.09 (1.071.11) 
1.08 
(1.061.09) 
Moderate/Severe 1.28 (1.261.30) 
1.22 
(1.201.25) 
Incident ESRD 1,471 (0.4) 128,884 (30.8) 
Mild 1.15 (1.021.30) 
1.13 
(1.011.28) 
Moderate/Severe 1.38 (1.211.57) 
1.27 
(1.121.45) 
 
Abbreviations: CKD = chronic kidney disease; ESRD = end-stage renal disease; HR = hazard ratio; SHR 
= subhazard ratio 
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Table 6. Renal outcomes associated with constipation status and constipation severity in 
Cox models (for incident CKD and ESRD) and multinomial logistic regression models (for 
change in eGFR) after fully-adjustment with multiple imputations for missing data (n = 
3,504,732) 
 
 
Incident CKD Incident ESRD 
Rapid eGFR 
decline* 
 HR (95% CI) HR (95% CI) OR (95% CI) 
Constipation status 
   
Presence of constipation 1.13 (1.121.14) 1.07 (1.001.16) 1.15 (1.131.18) 
Constipation Severity    
Mild 1.11 (1.101.13) 1.08 (0.981.19) 1.16 (1.131.20) 
Moderate/Severe 1.15 (1.131.17) 1.12 (1.011.25) 1.29 (1.251.34) 
 
*eGFR slope (mL/min/1.73 m
2
/year); <-10 versus -1 to <0 (reference) 
Abbreviations: CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; ESRD = 
end-stage renal disease; HR = hazard ratio; OR = odds ratio  
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Figure 1.  
 
 
 
Algorithm used to define the study cohort 
 
*Patients with the date of cohort entry later than the date of last encounter (n = 32,038), those with the 
date of incident ESRD later than the date of last encounter (n = 2,236), or those with an eGFR slope <-55 
(0.5th percentile) or ≥40 (99.5th percentile) mL/min/1.73 m2/year (n = 32,161). 
 
Abbreviations: eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; ICD = 
International Classification of Diseases 
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Figure 2.  
 
(A) 
a.       b. 
 
 
(B) 
a.       b. 
 
 
Unadjusted Kaplan-Meier cumulative-event curves for (A) incidence of CKD and (B) 
incident ESRD according to (a) constipation status and (b) its severity 
 
Cumulative incidences of (A) CKD and (B) ESRD were higher in patients with (versus without) 
constipation and with more severe constipation. 
 
Abbreviations: CKD = chronic kidney disease; ESRD = end-stage renal disease 
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Figure 3.  
 
(A)          (B) 
            
 
(C) 
 
 
Association of the presence of constipation with renal events: (A) incident CKD, (B) 
incident ESRD, and (C) change in eGFR 
 
The presence of constipation was associated with higher risk of incident CKD and ESRD and faster eGFR 
decline, compared with the absence of constipation. 
Estimates were calculated using Cox-proportional models (for incident CKD and ESRD) and multinomial 
logistic regression models (for change in eGFR). Models represent unadjusted association (model 1) and 
associations after adjustment for age, gender, race, and baseline eGFR (model 2); model 2 variables plus 
comorbidities (diabetes mellitus, hypertension, coronary heart disease, congestive heart failure, 
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cerebrovascular disease, peripheral arterial disease, peptic ulcer disease, rheumatic disease, malignancy, 
depression, liver disease, chronic lung disease, human immunodeficiency virus/acquired 
immunodeficiency syndrome, and bowel disorders) (model 3); model 3 plus baseline body mass index, 
systolic blood pressure, and diastolic blood pressure (model 4); model 4 plus socioeconomic parameters 
(mean per capita income, marital status, service connectedness, housing stress, low education, low 
employment, persistent poverty), number of VA healthcare encounters, cumulative length of 
hospitalization, receipt of influenza vaccination(s), and use of angiotensin-converting enzyme 
inhibitors/angiotensin-receptor blockers, statins, antidepressants, non-opioid analgesics, and opioids 
(model 5). 
 
Abbreviations: CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; ESRD = 
end-stage renal disease; VA = Veterans Affairs  
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Figure 4.  
 
(A)          (B) 
       
 
    (C) 
 
 
Association of constipation severity with renal events: (A) incident CKD, (B) incident 
ESRD, and (C) change in eGFR. Mild (blank symbols) and moderate/severe (filled 
symbols) constipation vs. absent constipation (reference). 
 
More severe constipation was associated with incrementally higher risk of incident CKD and ESRD and 
faster eGFR decline, compared with the absence of constipation. 
Estimates were calculated using Cox-proportional models (for incident CKD and ESRD) and multinomial 
logistic regression models (for change in eGFR). Models represent unadjusted association (model 1) and 
associations after adjustment for age, gender, race, and baseline eGFR (model 2); model 2 variables plus 
comorbidities (diabetes mellitus, hypertension, coronary heart disease, congestive heart failure, 
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cerebrovascular disease, peripheral arterial disease, peptic ulcer disease, rheumatic disease, malignancy, 
depression, liver disease, chronic lung disease, human immunodeficiency virus/acquired 
immunodeficiency syndrome, and bowel disorders) (model 3); model 3 plus baseline body mass index, 
systolic blood pressure, and diastolic blood pressure (model 4); model 4 plus socioeconomic parameters 
(mean per capita income, marital status, service connectedness, housing stress, low education, low 
employment, persistent poverty), number of VA healthcare encounters, cumulative length of 
hospitalization, receipt of influenza vaccination(s), and use of angiotensin-converting enzyme 
inhibitors/angiotensin-receptor blockers, statins, antidepressants, non-opioid analgesics, and opioids 
(model 5). 
 
Abbreviations: CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; ESRD = 
end-stage renal disease, VA = Veterans Affairs 
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Figure 5.  
 
(A)          (B)   (C)  
 
 
Association of the presence of constipation with (A) incident CKD, (B) incident ESRD, and 
(C) change in eGFR in predefined subgroups of the overall cohort 
 
The presence (versus absence) of constipation was associated with higher risk of incident CKD and 
ESRD and faster eGFR decline in most subgroups. 
Estimates were calculated using Cox-proportional models (for incident CKD and ESRD) and multinomial 
logistic regression models (for eGFR slope [mL/min/1.73 m
2
/year]; <-10 vs. -1 to <0 [reference]). 
Data were adjusted for age, gender, race, baseline eGFR, comorbidities (diabetes mellitus, hypertension, 
coronary heart disease, congestive heart failure, cerebrovascular disease, peripheral arterial disease, peptic 
ulcer disease, rheumatic disease, malignancy, depression, liver disease, chronic lung disease, human 
immunodeficiency virus/acquired immunodeficiency syndrome, and bowel disorders), baseline body 
mass index, systolic blood pressure, diastolic blood pressure, socioeconomic parameters (mean per capita 
income, marital status, service connectedness, housing stress, low education, low employment, persistent 
poverty), number of VA healthcare encounters, cumulative length of hospitalization, receipt of influenza 
vaccination(s), and use of angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers, statins, 
antidepressants, non-opioid analgesics, and opioids. 
 
Abbreviations: CHD = coronary heart disease; CHF = congestive heart failure; CKD = chronic kidney 
disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal 
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disease; HTN = hypertension; VA = Veterans Affairs  
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Figure 6.  
 
(A)         (B)   (C) 
 
 
Association of the presence of constipation with (A) incident CKD, (B) incident ESRD, and 
(C) change in eGFR in predefined subgroups in a propensity-matched cohort 
 
The presence (versus absence) of constipation was associated with higher risk of incident CKD and 
ESRD and faster eGFR decline in most subgroups. 
Estimates were calculated using Cox-proportional models (for incident CKD and ESRD) and multinomial 
logistic regression models (for eGFR slope [mL/min/1.73 m
2
/year]; <-10 vs. -1 to <0 [reference]).  
 
Abbreviations: CHD = coronary heart disease; CHF = congestive heart failure; CKD = chronic kidney 
disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal 
disease; HTN = hypertension  
